TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presentado dom, 30 ago · 08:43 CESTHot Line 6Todos los ensayos Hot Line →

Met-HeFT

2026

Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance — Metformin Heart Failure Trial (Met-HeFT), component of DANHEART

In 940 patients with HFrEF and diabetes or insulin resistance, metformin did not reduce death, worsening heart failure, myocardial infarction or stroke compared with placebo.

Resultado

Eficacia: Time to first occurrence of the composite of death, hospitalisation with worsening heart failure (including an urgent visit requiring intravenous therapy or metolazone, heart transplantation or LVAD implantation), acute myocardial infarction or strokeHR 1,10 (IC del 95% 0,84-1,42) · P = 0,48

Por debajo de 1 a favor de metformin, por encima de 1 a favor de placebo.

Tasas de eventos
Diferencia absoluta
1,7 puntos

La diferencia absoluta se deriva de las tasas de eventos.

También se informa: All-cause death, unplanned heart failure hospitalisation, new-onset diabetes and the change in NT-proBNP were all unaffected. No harm signal.

Publicación original
Subtema
Metabolic therapy
Diseño
investigator-initiated, multicentre (23 centres in Denmark), randomised 1:1, double-blind, placebo-controlled, event-driven; 2 × 2 factorial with H-HeFT; metformin 500 mg tablets uptitrated to 1,000 mg twice daily (500 mg twice daily if eGFR 35–60 mL/min/1.73 m²) vs matching placebo, with dose reduction or pausing for declining renal function or acute illness; mean follow-up 3.7 years
Relevancia
Importante: uno de varios pilares.
Fuente
Presented at ESC Congress 2026, Hot Line 6, 30 August.

Discusión y crítica

Metformin's reputation for cardioprotection rests on a 1998 substudy and a great deal of observational data; randomised against placebo on top of modern heart failure therapy, it does nothing to events in either direction. The population is the catch and the investigators say so: barely one in ten had established type 2 diabetes, because patients already taking metformin could not be asked to stop, so this is mostly prediabetes and insulin resistance. It settles the cardioprotection question for that group and leaves the drug where it belongs: a glucose-lowering agent that is safe in heart failure.